Gilead Details Strong Sovaldi Launch, Plans HCV Combo Pill Filing
This article was originally published in The Pink Sheet Daily
Less than one month after U.S. approval, the HCV drug has posted sales of $139 million, with about 70% of use occurring in patients carrying genotype 1 of the virus. Gilead reported 21% sales growth for the fourth quarter of 2013, 15% for the full year.
You may also be interested in...
The US agency’s 2021 device funding request for $21m above its 2020 budget will be frozen under a continuing resolution, making planning difficult.
Bakul Patel, director of the US agency’s new Digital Health Center of Excellence, tells Medtech Insight he’s looking to hire staff that want to shape the digital health regulatory landscape.
No device-related warning letters were released by the US FDA the week of 29 September.